NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:NBIX • US64125C1099

141.2 USD
+3.27 (+2.37%)
At close: Feb 6, 2026
140.359 USD
-0.84 (-0.6%)
After Hours: 2/6/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to NBIX. NBIX was compared to 523 industry peers in the Biotechnology industry. NBIX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. NBIX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make NBIX suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year NBIX was profitable.
  • NBIX had a positive operating cash flow in the past year.
  • Each year in the past 5 years NBIX has been profitable.
  • Each year in the past 5 years NBIX had a positive operating cash flow.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • NBIX's Return On Assets of 10.03% is amongst the best of the industry. NBIX outperforms 93.90% of its industry peers.
  • Looking at the Return On Equity, with a value of 14.25%, NBIX belongs to the top of the industry, outperforming 94.48% of the companies in the same industry.
  • NBIX has a better Return On Invested Capital (11.10%) than 95.05% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for NBIX is significantly below the industry average of 18.12%.
Industry RankSector Rank
ROA 10.03%
ROE 14.25%
ROIC 11.1%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

  • NBIX's Profit Margin of 15.95% is amongst the best of the industry. NBIX outperforms 92.38% of its industry peers.
  • NBIX's Profit Margin has improved in the last couple of years.
  • NBIX has a better Operating Margin (20.64%) than 95.05% of its industry peers.
  • NBIX's Operating Margin has declined in the last couple of years.
  • NBIX's Gross Margin of 98.37% is amongst the best of the industry. NBIX outperforms 97.71% of its industry peers.
  • In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
Industry RankSector Rank
OM 20.64%
PM (TTM) 15.95%
GM 98.37%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NBIX is still creating some value.
  • The number of shares outstanding for NBIX has been increased compared to 1 year ago.
  • The number of shares outstanding for NBIX has been increased compared to 5 years ago.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • NBIX has an Altman-Z score of 8.27. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • NBIX has a Altman-Z score of 8.27. This is in the better half of the industry: NBIX outperforms 79.43% of its industry peers.
  • There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.27
ROIC/WACC1.26
WACC8.82%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • NBIX has a Current Ratio of 3.38. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
  • NBIX's Current ratio of 3.38 is in line compared to the rest of the industry. NBIX outperforms 40.76% of its industry peers.
  • A Quick Ratio of 3.27 indicates that NBIX has no problem at all paying its short term obligations.
  • The Quick ratio of NBIX (3.27) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.27
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.06% over the past year.
  • NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 58.39% yearly.
  • Looking at the last year, NBIX shows a quite strong growth in Revenue. The Revenue has grown by 19.61% in the last year.
  • The Revenue has been growing by 24.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%

3.2 Future

  • Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.54% on average per year.
  • Based on estimates for the next years, NBIX will show a quite strong growth in Revenue. The Revenue will grow by 12.05% on average per year.
EPS Next Y55.53%
EPS Next 2Y49.21%
EPS Next 3Y39.31%
EPS Next 5Y32.54%
Revenue Next Year21.06%
Revenue Next 2Y20.26%
Revenue Next 3Y16.24%
Revenue Next 5Y12.05%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 33.78, which means the current valuation is very expensive for NBIX.
  • Based on the Price/Earnings ratio, NBIX is valued cheaply inside the industry as 92.57% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of NBIX to the average of the S&P500 Index (27.93), we can say NBIX is valued slightly more expensively.
  • A Price/Forward Earnings ratio of 19.28 indicates a rather expensive valuation of NBIX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 93.90% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of NBIX to the average of the S&P500 Index (27.77), we can say NBIX is valued slightly cheaper.
Industry RankSector Rank
PE 33.78
Fwd PE 19.28
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 94.29% of the companies listed in the same industry.
  • NBIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.86% of the companies in the same industry.
Industry RankSector Rank
P/FCF 23.74
EV/EBITDA 20.9
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
  • NBIX's earnings are expected to grow with 39.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.61
PEG (5Y)0.58
EPS Next 2Y49.21%
EPS Next 3Y39.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NBIX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (2/6/2026, 8:00:01 PM)

After market: 140.359 -0.84 (-0.6%)

141.2

+3.27 (+2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28
Earnings (Next)02-11
Inst Owners99.58%
Inst Owner Change-0.07%
Ins Owners1.01%
Ins Owner Change0.94%
Market Cap14.08B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target182.16 (29.01%)
Short Float %3.58%
Short Ratio3.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)0.17%
PT rev (3m)5.64%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)2.65%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)1.35%
Revenue NQ rev (1m)-1.34%
Revenue NQ rev (3m)-1.39%
Revenue NY rev (1m)-0.34%
Revenue NY rev (3m)-0.34%
Valuation
Industry RankSector Rank
PE 33.78
Fwd PE 19.28
P/S 5.25
P/FCF 23.74
P/OCF 22.11
P/B 4.69
P/tB 4.74
EV/EBITDA 20.9
EPS(TTM)4.18
EY2.96%
EPS(NY)7.32
Fwd EY5.19%
FCF(TTM)5.95
FCFY4.21%
OCF(TTM)6.39
OCFY4.52%
SpS26.91
BVpS30.12
TBVpS29.77
PEG (NY)0.61
PEG (5Y)0.58
Graham Number53.23
Profitability
Industry RankSector Rank
ROA 10.03%
ROE 14.25%
ROCE 15.26%
ROIC 11.1%
ROICexc 16.02%
ROICexgc 16.25%
OM 20.64%
PM (TTM) 15.95%
GM 98.37%
FCFM 22.11%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 147.14%
Cap/Sales 1.63%
Interest Coverage 250
Cash Conversion 109.17%
Profit Quality 138.57%
Current Ratio 3.38
Quick Ratio 3.27
Altman-Z 8.27
F-Score5
WACC8.82%
ROIC/WACC1.26
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y55.53%
EPS Next 2Y49.21%
EPS Next 3Y39.31%
EPS Next 5Y32.54%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.06%
Revenue Next 2Y20.26%
Revenue Next 3Y16.24%
Revenue Next 5Y12.05%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year4.31%
EBIT Next 3Y21.9%
EBIT Next 5Y18.39%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%

NEUROCRINE BIOSCIENCES INC / NBIX FAQ

What is the fundamental rating for NBIX stock?

ChartMill assigns a fundamental rating of 7 / 10 to NBIX.


What is the valuation status for NBIX stock?

ChartMill assigns a valuation rating of 7 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.


What is the profitability of NBIX stock?

NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for NBIX stock?

The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 33.78 and the Price/Book (PB) ratio is 4.69.